Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


31.07.2017

1 BMC Cancer
1 Br J Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
5 Gynecol Oncol
1 Int J Cancer
2 J Clin Oncol
1 Obstet Gynecol
1 Oncol Rep
1 PLoS One
2 Tumour Biol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. MAATTA KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, et al
    Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    BMC Cancer. 2017;17:496.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. MENON U, McGuire AJ, Raikou M, Ryan A, et al
    The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer Lett

  3. SAKAI K, Ukita M, Schmidt J, Wu L, et al
    Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
    Cancer Lett. 2017 Jul 19. pii: S0304-3835(17)30439.
    PubMed     Text format     Abstract available


    Cancer Res

  4. ZHU W, Jarman KE, Lokman NA, Neubauer HA, et al
    CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1.
    Cancer Res. 2017 Jul 20. pii: canres.0025.2017.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  5. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  6. WEN Q, Shao Z, Zhang P, Zhu T, et al
    Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy.
    Eur J Obstet Gynecol Reprod Biol. 2017;216:85-91.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  7. CRIM A, Rowland M, Ruskin R, Dvorak J, et al
    Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Gynecol Oncol. 2017;146:268-272.
    PubMed     Text format     Abstract available

  8. KUMAR A, Langstraat CL, DeJong SR, McGree ME, et al
    Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)31163.
    PubMed     Text format     Abstract available

  9. PHIPPEN NT, Secord AA, Wolf S, Samsa G, et al
    Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
    Gynecol Oncol. 2017 Jul 22. pii: S0090-8258(17)31138.
    PubMed     Text format     Abstract available

  10. ADAM JP, Boumedien F, Letarte N, Provencher D, et al
    Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jul 21. pii: S0090-8258(17)31160.
    PubMed     Text format     Abstract available

  11. MILLER EM, Tymon-Rosario J, Xie X, Xue X, et al
    Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31169.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. WU AH, Pearce CL, Lee A, Tseng C, et al
    Timing of births and oral contraceptive use influences ovarian cancer risk.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30910.
    PubMed     Text format     Abstract available


    J Clin Oncol

  13. SHAIKH F, Cullen JW, Olson TA, Pashankar F, et al
    Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017;35:1203-1210.
    PubMed     Text format     Abstract available

  14. LHEUREUX S, Bruce JP, Burnier JV, Karakasis K, et al
    Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    J Clin Oncol. 2017;35:1240-1249.
    PubMed     Text format     Abstract available


    Obstet Gynecol

  15. MARTINELLI F, Ditto A, Bogani G, Raspagliesi F, et al
    Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017;130:469-470.
    PubMed     Text format    


    Oncol Rep

  16. GUO X, Guo N, Zhao J, Cai Y, et al
    Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells.
    Oncol Rep. 2017 Jul 18. doi: 10.3892/or.2017.5829.
    PubMed     Text format     Abstract available


    PLoS One

  17. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    PubMed     Text format     Abstract available


    Tumour Biol

  18. ZHANG J, Jiang Y, Zhao Y, Wang W, et al
    Downregulation of tyrosine threonine kinase inhibits tumor growth via G2/M arrest in human endometrioid endometrial adenocarcinoma.
    Tumour Biol. 2017;39:1010428317712444.
    PubMed     Text format     Abstract available

  19. SUN Y, Fan X, Zhang Q, Shi X, et al
    Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.
    Tumour Biol. 2017;39:1010428317712592.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: